H1N1 influenza virus cold-adapted vaccine backbone strain CV2-PR8 and its construction method and application
By constructing biological materials for recombinant influenza A viruses, solving the effectiveness and safety of influenza vaccines, a new influenza cold-adapted vaccine skeleton strain is provided for remodeling with the HA and NA genes of the epidemic influenza viruses, improving The immunity of the flu vaccine and enhances safety.
Patent Information
- Application Number
- CN202310662031.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-30
- Filing Date
- 2023-06-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-06-06
AI Technical Summary
The reduction in effectiveness and safety of existing influenza vaccines is mainly due to the large difference between the vaccine skeleton strains used and the currently prevalent strains, resulting in a decrease in immunogenicity of live attenuated vaccines and vaccine strain mutations.
Constructing biological materials for recombinant influenza A virus, including protein composition and complete sets of DNA molecules, construct recombinant vectors through reverse genetics rescue system plasmids, and generate influenza virus genomic RNA, which is used to prepare cold-adapted influenza strains as vaccine backbone poisons plant.
It provides a new influenza cold-adaptive vaccine skeleton strain that can be reconstituted with the HA and NA genes of the epidemic influenza viruses, improves the immune effect of the influenza vaccine, and makes up for the lack of intellectual property rights and products of existing cold-adaptive attenuated vaccines. And enhance the safety of the vaccine.
Smart Images

Figure BDA0004269439780000091 
Figure BDA0004269439780000121 
Figure HDA0004269439800000011
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of medical preparations, and specifically relates to an H1N1 influenza virus cold-adapted vaccine backbone strain CV2-PR8 and a construction method and application thereof. Background Art
[0002] Influenza virus is a segmented single-stranded negative-strand RNA virus, which is divided into four types: A, B, C and D. At present, the main influenza viruses prevalent in the human population are the A-type H1N1 and H3N2 subtypes and the B-type Yamagata and Victoria seasonal influenza viruses. So far, influenza viruses have caused four pandemics, namely the H1N1 subtype in 1918, the H2N2 subtype in 1957, the H3N2 subtype in 1968, and the H1N1 subtype in 2009. Each time, it has brought great harm to the lives and health of people all over the world. Since the emergence of influenza, seasonal influenza has been prevalent and occurred every year around the world, bringing a serious disease burden to society.
[0003] Influenza vaccine is currently the most effective way to prevent influenza virus infection and epidemic. There are several types of influenza vaccine, including inactivated influenza vaccine and live attenuated vaccine. Inactivated vaccine is the vaccine we use most frequently. The inactivated influenza vaccine strains currently used are mainly the six internal gene segments of the A / Puerto Rico / 8 / 1934 (PR8) (H1N1) backbone strain adapted to chicken embryos, and the HA and NA gene segments of the epidemic strain recommended by WHO, which are constructed by reassortment. This type of vaccine mainly works by inducing the body to produce humoral immunity, showing the characteristics of short protection time and poor cross-protection.
[0004] There are two main donor skeletons for the currently approved live attenuated influenza A virus vaccines, namely A / Leningrad / 17 / 57H2N2 LAIV (Len LAIV) and A / Ann Arbor / 6 / 60H2N2 (AA / 60). The live attenuated vaccine is constructed by reassortment of the six internal genes of the donor strain with the HA and NA genes of the epidemic virus recommended by the WHO. The live attenuated vaccine is mainly administered by nasal spray, which mimics the route of natural infection and can simultaneously induce humoral immunity, cellular immunity and immune response in the host. The cellular immune response plays an important role in cross-immunity protection against different subtypes of viruses.
[0005] However, current studies have shown that the effectiveness of approved live attenuated vaccines has declined. This decline in immunogenicity is likely caused by the large difference between the vaccine backbone strain used and the currently circulating strain. The H2N2 subtype influenza virus disappeared from the population long ago, and the current circulating strains are mainly H1N1 and H3N2 subtype influenza viruses. In addition, vaccine strain mutations have been found in the production process of live attenuated vaccines and in children who have received live attenuated vaccines, which has also raised questions about the safety of currently used live attenuated vaccines. All these phenomena suggest that a new live attenuated influenza vaccine backbone needs to be constructed. Summary of the invention
[0006] The technical problem to be solved by the present invention is: how to prepare a cold-adapted influenza strain as a cold-adapted vaccine backbone strain for preparing an influenza vaccine.
[0007] In order to solve the above technical problems, the present invention provides a biological material for constructing a recombinant influenza A virus in the first aspect, characterized in that: the biological material is selected from any one of the following B1)-B7):
[0008] B1) a protein composition, the protein composition comprising a PB2 mutant protein, a PB1 mutant protein, a PA mutant protein, a NP mutant protein, an M1 mutant protein and an M2 mutant protein,
[0009] The PB2 mutant protein is selected from A1) or A2):
[0010] A1), a protein having an amino acid sequence of SEQ ID No. 1;
[0011] A2), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1);
[0012] The PB1 mutant protein is selected from A3) or A4):
[0013] A3), a protein having an amino acid sequence of SEQ ID No. 2;
[0014] A4), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A3);
[0015] The PA mutant protein is selected from A5) or A6):
[0016] A5), a protein having an amino acid sequence of SEQ ID No. 3;
[0017] A6), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A5);
[0018] The NP mutant protein is selected from A7) or A8):
[0019] A7), a protein having an amino acid sequence of SEQ ID No. 4;
[0020] A8), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A7);
[0021] The M1 mutant protein is selected from A9) or A10):
[0022] A9), a protein having an amino acid sequence of SEQ ID No. 7;
[0023] A10), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A11);
[0024] The M2 mutant protein is selected from A11) or A12):
[0025] A11), a protein having an amino acid sequence of SEQ ID No. 8;
[0026] A12), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A13);
[0027] B2), a set of DNA molecules encoding the protein composition described in B1) (DNA molecule composition), wherein the set of DNA molecules comprises a DNA molecule encoding the PB2 mutant protein, a DNA molecule encoding the PB1 mutant protein, a DNA molecule encoding the PA mutant protein, a DNA molecule encoding the NP mutant protein, and a DNA molecule encoding the M1 mutant protein and the M2 mutant protein,
[0028] B3), a set of vectors (vector compositions), including the following B3a), B3b), B3c), B3d) and B3e), B3a), a recombinant vector containing a DNA molecule encoding the PB2 mutant protein;
[0029] B3b), a recombinant vector containing a DNA molecule encoding the PB1 mutant protein;
[0030] B3c), a recombinant vector containing a DNA molecule encoding the PA mutant protein;
[0031] B3d), a recombinant vector containing a DNA molecule encoding the NP mutant protein;
[0032] B3e), a recombinant vector containing a DNA molecule encoding the M1 mutant protein and the M2 mutant protein;
[0033] B4), a microorganism containing the set of DNA molecules described in B2) or the set of vectors described in B3);
[0034] B5), an animal cell line containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3);
[0035] B6) Animal tissues containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3);
[0036] B7) Animal organs containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3).
[0037] Furthermore, in the biological material, the protein composition described in B1) further comprises HA protein, NA protein, NS1 protein and NS2 protein of influenza A virus,
[0038] The NS1 protein is selected from A13) or A14), and the NS2 protein is selected from A15) or A16):
[0039] A13), a protein having an amino acid sequence of SEQ ID No. 5;
[0040] A14), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A13);
[0041] A15), a protein having an amino acid sequence of SEQ ID No. 6;
[0042] A16), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A15);
[0043] The HA protein is selected from A17) or A18):
[0044] A17), a protein having an amino acid sequence of SEQ ID No. 9;
[0045] A18), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A17);
[0046] The NA protein is selected from A19) or A20):
[0047] A19), a protein having an amino acid sequence of SEQ ID No. 9;
[0048] A20), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A19).
[0049] In the present invention, the protein tag refers to a polypeptide or protein that is fused and expressed with a target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a Flag protein tag, a His protein tag, an MBP protein tag, an HA protein tag, a myc protein tag, a GST protein tag and / or a SUMO protein tag, etc.
[0050] Furthermore, in the biological material, B2) the set of DNA molecules further includes a DNA molecule encoding the HA protein of the influenza A virus, a DNA molecule encoding the NA protein of the influenza A virus, and a DNA molecule encoding the NS1 protein and NS2 protein of the influenza A virus.
[0051] Furthermore, in the biological material, the nucleotide sequence of the DNA molecule encoding the PB2 mutant protein is SEQ ID No.31; the nucleotide sequence of the DNA molecule encoding the PB1 mutant protein is SEQ ID No.32; the nucleotide sequence of the DNA molecule encoding the PA mutant protein is SEQ ID No.33; the nucleotide sequence of the DNA molecule encoding the NP mutant protein is SEQ ID No.34; and the nucleotide sequence of the DNA molecule encoding the M1 mutant protein and the M2 mutant protein is SEQ ID No.36.
[0052] Furthermore, in the biological material, the set of vectors described in B3) also includes B3f)-B3h),
[0053] B3f), a recombinant vector containing a DNA molecule encoding the NS1 protein and the NS2 protein of influenza A virus;
[0054] B3g), a recombinant vector containing a DNA molecule encoding the HA protein of influenza A virus;
[0055] B3h), a recombinant vector containing a DNA molecule encoding the NA protein of influenza A virus.
[0056] Furthermore, in the biological material, the nucleotide sequence of the DNA molecule encoding the NS1 protein and NS2 protein of influenza A virus is SEQ ID No.35; the nucleotide sequence of the DNA molecule encoding the HA protein of influenza A virus is SEQ ID No.37; and the nucleotide sequence of the DNA molecule encoding the NA protein of influenza A virus is SEQ ID No.38.
[0057] Furthermore, in the biological material, the DNA molecule encoding the HA protein of the influenza A virus and the DNA molecule encoding the NA protein of the influenza A virus can be adaptively adjusted according to the type of the epidemic influenza A virus to ensure that the HA and NA in the recombinant process virus are the same as the epidemic influenza A virus.
[0058] In the present invention, the vector can be a reverse genetics rescue system plasmid of influenza virus, such as a virus rescue system plasmid. In one embodiment of the present invention, the virus rescue system plasmid is pHW2000. The cDNA of each segment genome of influenza virus is constructed into the virus rescue system plasmid to obtain a recombinant vector, and the plasmids of all segments are co-transfected into cells, and the recombinant vector can generate the genomic RNA of influenza virus, and can also generate influenza virus protein to obtain a recombinant influenza virus.
[0059] In a second aspect, the present invention provides a recombinant influenza A virus, wherein the recombinant influenza A virus expresses or contains the above-mentioned protein composition.
[0060] Furthermore, the genome of the recombinant influenza A virus is a single-stranded negative-stranded, segmented RNA, and the single-stranded negative-stranded, segmented RNA is transcribed to obtain a set of positive-stranded RNAs complementary to the single-stranded negative-stranded, segmented RNAs, and the set of positive-stranded RNAs includes PB2-RNA, PB1-RNA, PA-RNA, NP-RNA and M-RNA, and the PB2-RNA is an RNA molecule encoding the above-mentioned PB2 mutant protein; the PB1-RNA is an RNA molecule encoding the above-mentioned PB2 mutant protein; the PA-RNA is an RNA molecule encoding the above-mentioned PA mutant protein; the NP-RNA is an RNA molecule encoding the above-mentioned NP mutant protein; and the M-RNA is an RNA molecule encoding the above-mentioned M1 protein and M2 protein.
[0061] Furthermore, the set of positive-strand RNA in the recombinant influenza A virus also includes NS-RNA, HA-RNA and NA-RNA, wherein the NS-RNA is an RNA molecule encoding the above-mentioned NS mutant protein; the HA-RNA is an RNA molecule encoding the above-mentioned HA protein; and the NA-RNA is an RNA molecule encoding the above-mentioned NA protein.
[0062] Furthermore, in the recombinant influenza A virus, the PB2-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.11; the PB1-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.12; the PA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.13; the NP-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.14; and the M-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.16.
[0063] Furthermore, in the recombinant influenza A virus, the NS-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.15; the HA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.17; and the NA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.18.
[0064] Furthermore, in the recombinant influenza A virus, the HA-RNA and NA-RNA can also be adaptively adjusted according to the type of pandemic influenza A virus to ensure that the sequences of the HA-RNA and NA-RNA in the recombinant influenza A virus are identical to those of the pandemic influenza A virus.
[0065] Furthermore, the strain number of the recombinant influenza A virus is CV2-A / Puerto Rico / 8 / 1934 (PR8) (H1N1), and its deposit number in the General Microbiological Center of China National Microbiological Culture Collection is CGMCC No. 45374.
[0066] In a third aspect, the present invention provides a method for constructing a recombinant influenza A virus, the method comprising M1) or / and M2),
[0067] M1), introducing the above-mentioned complete set of vectors, the recombinant vector containing the gene encoding the NS protein of influenza A virus, the recombinant vector containing the gene encoding the HA protein of the pandemic influenza A virus, and the recombinant vector containing the gene encoding the NA protein of the pandemic influenza A virus into cells to obtain a recombinant influenza A virus containing the HA and NA of the pandemic influenza A virus;
[0068] M2), the above-mentioned recombinant influenza A virus is mixed and cultured with the epidemic influenza A virus to obtain the recombinant influenza A virus containing the HA and NA of the epidemic influenza A virus.
[0069] Furthermore, in the method, the cell may be a packaging cell. In one embodiment of the present invention, M1) the method comprises introducing the above-mentioned vector into MDCK and 293T cells, transfecting the mixed cell culture into chicken embryos, and then collecting the chicken embryo allantoic fluid to obtain EggP1 containing the recombinant influenza virus CV-PR8 backbone strain.
[0070] In a fourth aspect, the present invention provides use of the above-mentioned recombinant influenza virus or the above-mentioned biological material in the preparation of a drug for preventing and / or treating influenza virus.
[0071] In a fifth aspect, the present invention provides the use of the above-mentioned recombinant influenza virus or the above-mentioned biological material in the preparation of influenza vaccine.
[0072] In a sixth aspect, the present invention provides an influenza vaccine, wherein the influenza vaccine uses the above-mentioned recombinant influenza A virus as a backbone strain or as an active ingredient.
[0073] In the present invention, the backbone strain may be an influenza virus containing the above-mentioned PB2 mutant protein, PB1 mutant protein, PA mutant protein, NP mutant protein, M1 mutant protein, M2 mutant protein and corresponding genome. The HA protein and NA protein and their corresponding genome sequences may be adaptively adjusted according to the type of epidemic influenza A virus to ensure that the influenza vaccine produces an immune effect on the target epidemic influenza A strain.
[0074] Beneficial technical effects achieved by the present invention
[0075] The influenza cold-adapted vaccine skeleton strain obtained by the present invention can be used as a cold-adapted vaccine skeleton strain, and reconstructed with the HA and NA genes of the popular influenza virus to prepare an influenza vaccine. At present, the intellectual property rights and products of the influenza virus cold-adapted attenuated vaccine skeleton in my country are seriously lacking, and the present invention can make up for this gap. At the same time, the immune effect of the influenza virus cold-adapted attenuated vaccine currently approved internationally has a downward trend, and some studies have raised questions about the safety of the vaccine. The present invention provides more options for the influenza virus cold-adapted attenuated vaccine skeleton strain.
[0076] Collection Instructions
[0077] Bacteria: Influenza virus type A
[0078] Latin name: Influenza A virus
[0079] Strain ID: CV2-A / PuertoRico / 8 / 1934(PR8)(H1N1)
[0080] Depository: China National Microbiological Culture Collection Administration General Microbiology Center
[0081] Abbreviation of depository institution: CGMCC
[0082] Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing
[0083] Deposit date: December 19, 2022
[0084] The registration number of the Collection Center is: CGMCC No.45374. BRIEF DESCRIPTION OF THE DRAWINGS
[0085] Figure 1 The replication ability of the constructed CV-PR8 backbone strain at different temperatures.
[0086] Figure 2 The replication ability of the constructed CV2-PR8 cold-adapted vaccine backbone strain under different temperature conditions.
[0087] Figure 3 Gel electrophoresis of PCR amplification products. DETAILED DESCRIPTION
[0088] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0089] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0090] The MDCK cells were kindly donated by Gao Fu's research group at the Institute of Microbiology, Chinese Academy of Sciences, and are disclosed in the document "Song H, Gao GF. Evaluation of the Glycan-Binding and Esterase Activities of Hemagglutinin-Esterase-Fusion Glycoprotein from Influenza D Virus. Methods Mol Biol. 2022; 2556: 187-203. doi: 10.1007 / 978-1-0716-2635-1_15. PMID: 36175636." The public can obtain the above-mentioned biological materials from the applicant. The obtained above-mentioned biological materials are only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0091] 293T cells were purchased from the Institute of Basic Medicine, Chinese Academy of Medical Sciences-Peking Union Medical College, with the cell number 1101HUM-PUMC000091 and order number: 2021010716891.
[0092] MDCK and 293T cells were cultured in DMEM (Gibco) containing 10% fetal bovine serum (Gibco) and double-antibody (100 U / mL penicillin + 100 μg / mL streptomycin) at 37°C and 5% CO. 2 The cells were cultured in an incubator. 9-11 day old SPF chicken embryos were obtained from Beijing Boehringer Ingelheim Biotech Co., Ltd. The pHW2000 vector in the following examples was constructed and published by Erich Hoffmann, and its nucleotide sequence is SEQ ID No.19.
[0093] The A / Anhui / 1 / 2005 (H5N1) and A / Hong Kong / 2108 / 2003 (H9N2) strains in the following examples were synthesized with corresponding cDNAs according to the genomic information provided by the GISAID accession number of the strains, and the corresponding strains were obtained by reverse genetics technology and virus rescue plasmids according to the method of Example 1 (the transfection temperature and chicken embryo culture temperature in Example 1 were both changed to 37° C.).
[0094] A / Guangdong-Maonan / SWL1536 / 2019 (H1N1) and A / Hong Kong / 2671 / 2019 (H3N2) in the following examples are strains provided by the Chinese Center for Disease Control and Prevention.
[0095] A / Anhui / 1 / 2013(H7N9) in the following examples is preserved in this laboratory and disclosed in the paper "Bi Y, Xie Q, Zhang S, Li Y, Xiao H, Jin T, Zheng W, Li J, Jia X, Sun L, Liu J, Qin C, Gao GF, Liu W. Assessment of the internal genes of influenza A(H7N9) virus contributing to high pathogenicity in mice. J Virol. 2015 Jan; 89(1): 2-13. doi: 10.1128 / JVI.02390-14. Epub 2014 Oct 15. ". The public may obtain the biological material from the applicant in accordance with relevant national biosafety regulations. The obtained biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0096] A / Shenzhen / TH002 / 2016(H5N6) in the following examples is preserved in this laboratory and disclosed in the paper "Bi Y, Tan S, Yang Y, Wong G, Zhao M, Zhang Q, Wang Q, Zhao X, Li L, Yuan J, Li H, Li H, Xu W, Shi W, Quan C, Zou R, Li J, Zheng H, Yang L, Liu WJ, Liu D, Wang H, Qin Y, Liu L, Jiang C, Liu W, Lu L, Gao GF, Liu Y. Clinical and Immunological Characteristics of Human Infections With H5N6 Avian Influenza Virus. Clin Infect Dis. 2019 Mar 19; 68(7): 1100-1109." The public may obtain the biological material from the applicant in accordance with relevant national biosafety regulations. The obtained biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0097] Example 1. Construction and cultivation of influenza virus CV-PR8 backbone strain
[0098] Through the reverse genetics operating system, based on the A / Puerto Rico / 8 / 1934 (PR8) (H1N1) vaccine backbone strain (also known as WT-PR8, genome publication number GenBank: AB671295.1), the mutant gene sites PB2 (N265S), PB1 (K391E, E581G, A661T), and NP (M239L) were artificially introduced to construct the CV-PR8 backbone strain.
[0099] 1) Obtaining CV-PR8 plasmid: Using the PR8 virus rescue system gene plasmid pHW2000 (the full sequence of the vector is SEQID No. 19) as the backbone vector, recombinant plasmids pHW2000-CV-PB2, pPHW2000-CV-PB1, pHW2000-CV-NP, pHW2000-CV-PA, pHW2000-CV-M, pHW2000-CV-NS, pHW2000-CV-HA and pHW2000-CV-NA were constructed respectively. Among them, CV-PB2 contains the mutation of N268S (CV-PB2), CV-PB1 contains the mutations of K391E, E581G, A661I (CV-PB1), and CV-NP has the mutation of M239L (CV-NP). These point mutations were completed by GenScript Biotech Co., Ltd.
[0100] The recombinant plasmid pHW2000-CV-PB2 is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-PB2) having a nucleotide sequence of SEQ ID No. 20, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-PB2 is transferred into cells, the cDNA of CV-PB2 generates the single-stranded negative-strand RNA of CV-PB2 of the influenza virus, and translates to obtain the influenza virus protein CV-PB2, the amino acid sequence of which is SEQ ID No. 25.
[0101] The recombinant plasmid pHW2000-CV-PB1 is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-PB1) having a nucleotide sequence of SEQ ID No.21, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-PB1 is transferred into cells, the cDNA of CV-PB1 generates the single-stranded negative-strand RNA of CV-PB1 of the influenza virus, and translates to obtain the influenza virus protein CV-PB1, and the amino acid sequence of the influenza virus protein CV-PB1 is SEQ ID No.26.
[0102] The recombinant plasmid pHW2000-CV-PA is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-PA) having a nucleotide sequence of SEQ ID No.22, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-PA is transferred into cells, the cDNA of CV-PA generates the single-stranded negative-strand RNA of CV-PA of influenza virus, and translates to obtain the influenza virus protein CV-PA, and the amino acid sequence of the influenza virus protein CV-PA is SEQ ID No.27.
[0103] The recombinant plasmid pHW2000-CV-NP is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-NP) having a nucleotide sequence of SEQ ID No.23, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-NP is transferred into cells, the cDNA of CV-NP generates the single-stranded negative-strand RNA of CV-NP of influenza virus, and translates to obtain the influenza virus protein CV-NP, the amino acid sequence of which is SEQ ID No.28.
[0104] The recombinant plasmid pHW2000-CV-NS is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-NS) having a nucleotide sequence of SEQ ID No.35, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-NS is transferred into cells, the cDNA of CV-NS generates the single-stranded negative-strand RNA of CV-NS of the influenza virus, and translates to obtain the influenza virus protein CV-NS1 and the influenza virus protein CV-NS2. The amino acid sequence of the influenza virus protein CV-NS1 is SEQ ID No.5, and the amino acid sequence of the influenza virus protein CV-NS2 is SEQ ID No.6.
[0105] The recombinant plasmid pHW2000-CV-M is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-M) having a nucleotide sequence of SEQ ID No.24, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-M is transferred into cells, the cDNA of CV-M generates the single-stranded negative-strand RNA of CV-M of the influenza virus, and translates to obtain influenza virus proteins CV-M1 and CV-M2, and the amino acid sequences of the influenza virus proteins CV-M1 and CV-M2 are SEQ ID No.29 and SEQ ID No.30, respectively.
[0106] The recombinant plasmid pHW2000-CV-HA is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-HA) having a nucleotide sequence of SEQ ID No.37, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-HA is transferred into cells, the cDNA of CV-HA is transcribed under the action of pol I to obtain the single-stranded negative-strand RNA of CV-HA of the influenza virus, and the single-stranded negative-strand RNA is transcribed under the action of pol II to obtain the positive-strand RNA (mRNA) of CV-HA of the influenza virus, and the positive-strand RNA of CV-HA of the influenza virus is further translated into the influenza virus protein CV-HA, and the amino acid sequence of the influenza virus protein CV-HA is SEQ ID No.9.
[0107] The recombinant plasmid pHW2000-CV-NA is a recombinant expression plasmid obtained by replacing the fragment between the BsmBI restriction sites of the backbone plasmid pHW2000 with a DNA molecule (cDNA of CV-NA) having a nucleotide sequence of SEQ ID No.38, while keeping the other nucleotide sequences of the backbone plasmid pHW2000 unchanged. After the recombinant plasmid pHW2000-CV-NA is transferred into cells, the cDNA of CV-NA is transcribed under the action of pol I to obtain the single-stranded negative-strand RNA of CV-NA of the influenza virus, and the single-stranded negative-strand RNA is transcribed under the action of pol II to obtain the positive-strand RNA (mRNA) of CV-NA of the influenza virus, and the positive-strand RNA of CV-NA of the influenza virus is further translated into the influenza virus protein CV-NA, and the amino acid sequence of the influenza virus protein CV-NA is SEQ ID No.10.
[0108] 2) Transfection method: MDCK:293T were plated in a six-well plate at a ratio of 1:5-10, and DMEM containing 10% fetal bovine serum and double antibody was used to incubate at 37°C and 5% CO 2 The cells were cultured in an incubator for 16-20 h before transfection experiments. During transfection, the recombinant plasmids pHW2000-CV-PB2, pHW2000-CV-PB1, pHW2000-CV-NP, pHW2000-CV-PA, pHW2000-CV-M, pHW2000-CV-NS, pHW2000-CV-HA and pHW2000-CV-NA and the transfection reagent Lipofectamine 2000 (500 ng of each recombinant plasmid and 10 μL of transfection reagent were added to each well of the six-well plate) were added to the EP tube containing MEM-optim (Gibco) and mixed evenly, and then allowed to stand for 5 minutes. The two were then mixed, and the mixture was allowed to stand for 20 minutes. The mixture was evenly added to the six-well plate and gently shaken to disperse the mixture evenly, and then placed at 33°C for 6-8 hours before changing the medium. Opti-MEM containing 1 μg / mL TPCK-trypsin (Sigma-Aldrich) was added to each well and placed at 33°C and 5% CO 2 After culturing in an incubator for 72 hours, two 9-11 day old SPF chicken embryos were inoculated with 500 μL of each chicken embryo, and the mixture was placed in a 33° C. incubator for 96 hours and then placed at 4° C. overnight. The chicken embryo allantoic fluid was then collected and its hemagglutination titer was measured with 1% chicken blood (Beijing Hute Biotechnology Co., Ltd.). If there was a hemagglutination titer, Egg P1 containing the recombinant influenza virus CV-PR8 backbone strain was obtained.
[0109] 3) Determination of growth curve: The growth curve of the strain was measured with chicken embryos, the virus was diluted 0.1 HAU times, the inoculation amount of each chicken embryo was 0.1 HAU / 100 μL, and a total of 9 SPF chicken embryos aged 9-11 days were inoculated. 3 chicken embryos were placed at 37°C, 33°C and 25°C, respectively. Then, 300 μL of chicken embryo allantoic fluid was extracted at 24h, 48h, 72h, 96h and 120h, respectively. The hemagglutination titer of the allantoic fluid was determined, and the CT value was determined using a qRT-PCR kit (Vazyme, Q223-01), and the copies (copy number) were calculated by the CT value (conversion formula: copies = -0.2654*CT value + 11.842, if there is no CT value, it is directly recorded as 0).
[0110] Kit model: Vazyme Q223-01, the nucleotide sequence of the primer probe used is as follows (5'-3'):
[0111] IFA-BF: TGGITAAAGACAAGACCAATCYTG;
[0112] IFA-BR:TCTACGYTGCWGTCCTCGCCTCA;
[0113] IFA-BP:TTGTRTTYACGCTCACCGTGCCCAG.
[0114] Wherein I represents inosine, Y represents T or C, W represents A or T, and R represents G or A.
[0115] The results are as follows Figure 1 As shown, Figure 1 The left side of the figure shows the hemagglutination titer of the allantoic fluid taken from the chicken embryos cultured at 37°C, 33°C and 25°C, wherein the ordinate is the HA titer and the abscissa is the culture time of the chicken embryos; Figure 1 The accompanying figure on the right side is the results of measuring the influenza virus copy number of the allantoic fluid taken from chicken embryos cultured at 37°C, 33°C and 25°C, wherein the ordinate is the logarithmic value (base 2) of the influenza virus copy number per unit volume (mL), and the abscissa is the culture time of the chicken embryos. Figure 1 The results showed that the constructed CV-PR8 backbone strain did not have the ability to replicate at 37°C, could replicate well at 33°C, but had poor replication ability at 25°C.
[0116] Example 2. Obtaining influenza virus cold-adapted vaccine strain CV2-PR8
[0117] The study found that the CV-PR8 backbone strain can replicate at 33°C, but not at 37°C and 25°C ( Figure 1). Therefore, in subsequent experiments, the following method was used for further cold adaptation and acclimation: the vaccine backbone strain CV-PR8 was continuously passaged at 25°C. During the passage process, we found that the strain gradually acquired the ability to replicate at 25°C, and finally obtained the cold-adapted strain CV2-PR8 (which has good replication ability at 25°C). Figure 2 ).
[0118] During the passage process, the changes in gene loci before, during and after cold adaptation were analyzed by first-generation and second-generation sequencing. The results showed that as the virus adapted to 25°C, adaptive mutations occurred in multiple genes (Table 1). Therefore, it was determined that these gene loci mutations gave the vaccine backbone strain CV2-PR8 the ability to grow at 25°C, and a cold-adapted vaccine backbone strain Egg P50 of H1N1 subtype influenza virus suitable for chicken embryo propagation was obtained. The Egg P50 strain was numbered as CV2-A / PuertoRico / 8 / 1934(PR8)(H1N1), hereinafter referred to as CV2-PR8. Moreover, CV2-PR8 was continuously passaged for 5 generations at 37°C and still could not grow at 37°C. This shows that the constructed cold-adapted vaccine backbone strain of H1N1 subtype influenza virus has good genetic stability and can be used as the backbone strain for the construction of influenza A cold-adapted vaccine strains. The HA and NA genes of the prevalent influenza virus are inserted into the vaccine backbone strain to construct a cold-adapted vaccine strain for the prevalent influenza virus.
[0119] The specific steps are as follows:
[0120] 1) Egg P50 subculture method: directly cold-adapt to subculture at 25°C. If the previous generation has no hemagglutination titer, directly inoculate the next generation with the original solution for subculture. The inoculation volume for each chicken embryo (9-11 days old) is 100 μL.
[0121] , after the inoculated chicken embryos were cultured in a 25°C incubator for 120 hours, they were placed in a 4°C refrigerator overnight, and then the chicken embryo allantoic fluid was collected and its hemagglutination titer and CT value were measured. If there was hemagglutination titer, 1HAU / 100μL and 0.1HAU / 100μL were inoculated for subculture, and after culturing at 25°C for 96h or 120h, they were placed in a 4°C refrigerator overnight, and then the chicken embryo allantoic fluid was collected and its hemagglutination titer was measured with 1% chicken blood, and its CT value was measured with a kit (Vazyme Q223-01).
[0122] 2) Determination of growth curve: The growth curve of the strain was measured with chicken embryos. The virus was diluted 0.1 HAU times, and the inoculation amount for each chicken embryo was 0.1 HAU / 100 μL. A total of 9 chicken embryos were inoculated. Three chicken embryos were placed at 37°C, 33°C and 25°C, respectively. Then, 300 μL of chicken embryo allantoic fluid was extracted at 24h, 48h, 72h, 96h and 120h, respectively, and the hemagglutination titer of the allantoic fluid taken at each time was measured.
[0123] 3) Determination of hemagglutination titer, i.e., HA titer: dilute the sample 2-fold in a 96-well V-bottom plate with 1×PBS, then add an equal volume of 1% suspended chicken red blood cells, let stand at room temperature for 20 minutes, and then read the hemagglutination titer of the sample by observing whether the chicken red blood cells settle.
[0124] The results of the hemagglutination titer test are as follows Figure 2 As shown, Figure 2 The middle coordinate is the logarithm of HA titer, and the horizontal coordinate is the chicken embryo culture time. Figure 2 The results showed that the strain had good replication ability at both 33°C and 25°C, but poor replication ability at 37°C.
[0125] 4) Detection of mutation sites of CV2-PR8
[0126] The RNA obtained from chicken embryo allantoic fluid was used as template (in ddH 2 O as a negative control), MBTuni-12 and MBTuni-13 were used as primers, and PCR amplification was performed using a PCR kit (Vazyme P611-01) to obtain PCR amplification products (the electrophoresis gel image is as follows), and the amplification products were sent for testing and second-generation sequencing. The sequencing results showed that compared with the backbone strain CV-PR8, the CV2-PR8 strain had mutations as shown in Table 1.
[0127] PCR amplification primer information:
[0128] MBTuni-12 ACg CgT gAT CAg CAA AAg CAg g;
[0129] MBTuni-13ACg CgT gAT CAg TAg AAA CAA gg.
[0130] PCR amplification product gel image Figure 3 shown.
[0131] Table 1: Adaptive mutation sites in CV2-PR8 (compared with CV-PR8)
[0132]
[0133] That is, compared with existing strains, the CV2-PR8 strain has the following mutations:
[0134] C1), influenza virus PB2 protein contains mutations N268S (backbone strain CV-PR8), Q439H, and V731M;
[0135] C2), influenza virus PB1 protein contains mutations K391E, E581G, A661I (backbone strain CV-PR8), R187K, and M645I;
[0136] C3), influenza virus PA protein contains mutations E243V, R269K, and E344K;
[0137] C4), the nucleoprotein (NP) of influenza virus contains mutations E18G, T130M, and M374I;
[0138] C5), influenza virus M1 protein contains the A137D mutation;
[0139] C6) The influenza virus M2 protein contains the A86S mutation.
[0140] That is, the sequencing results show that the CV2-PR8 strain expresses PB2 mutant protein, PB1 mutant protein, PA mutant protein, NP mutant protein, NS1 protein, NS2 protein, M1 mutant protein, M2 mutant protein, HA protein and NA protein. PB2 mutant protein is a protein with an amino acid sequence of SEQ ID No.1, PB1 mutant protein is a protein with an amino acid sequence of SEQ ID No.2, PA mutant protein is a protein with an amino acid sequence of SEQ ID No.3, NP mutant protein is a protein with an amino acid sequence of SEQ ID No.4, NS1 protein is a protein with an amino acid sequence of SEQ ID No.5, NS2 protein is a protein with an amino acid sequence of SEQ ID No.6, M1 mutant protein is a protein with an amino acid sequence of SEQ ID No.7, M2 mutant protein is a protein with an amino acid sequence of SEQ ID No.8, HA protein is a protein with an amino acid sequence of SEQ ID No.9, and NA protein is a protein with an amino acid sequence of SEQ ID No.10.
[0141] The genome of the CV2-PR8 influenza virus is a single-stranded negative-stranded, segmented RNA, which is transcribed to obtain a set of positive-stranded RNAs complementary to the single-stranded negative-stranded, segmented RNAs, and the set of positive-stranded RNAs includes PB2-RNA, PB1-RNA, PA-RNA, NP-RNA, NS-RNA, M-RNA, HA-RNA and NA-RNA. The PB2-RNA is an RNA molecule encoding the above-mentioned PB2 mutant protein, the PB1-RNA is an RNA molecule encoding the above-mentioned PB1 mutant protein, the PA-RNA is an RNA molecule encoding the above-mentioned PA mutant protein, and the NP-RNA is an RNA molecule encoding the above-mentioned NP mutant protein; the NS-RNA is an RNA molecule encoding the above-mentioned NS1 protein and NS2 protein, the M-RNA is an RNA molecule encoding the above-mentioned M1 mutant protein and M2 mutant protein, the HA-RNA is an RNA molecule encoding the above-mentioned HA protein, and the NA-RNA is an RNA molecule encoding the above-mentioned NA protein. That is, the PB2-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.11, the PB1-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.12, the PA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.13, the NP-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.14, the NS-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.15, the M-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.16, the HA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.17, and the NA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.18.
[0142] The obtained CV2-PR8 strain will be deposited under patent procedures at the General Microbiology Center of China National Microbiological Culture Collection Administration. The deposit date is December 19, 2022, and the registration number of the deposit center is CGMCC No.45374.
[0143] CV2-PR8 can be rescued and obtained by referring to the method of Example 1. Among them, the nucleotide sequence of the cDNA molecule of CV1-PB2 is SEQ ID No.31; the nucleotide sequence of the cDNA molecule of CV1-PB1 is SEQ ID No.32; the nucleotide sequence of the cDNA molecule of CV1-NP is SEQ ID No.33; the nucleotide sequence of the cDNA molecule of CV1-PA is SEQ ID No.34; the nucleotide sequence of the cDNA molecule of CV1-NS is SEQ ID No.35; the nucleotide sequence of the cDNA molecule of CV1-M is SEQ ID No.36; the nucleotide sequence of the cDNA molecule of CV1-HA is SEQ ID No.37; the nucleotide sequence of the DNA molecule of CV1-NA is SEQID No.38.
[0144] Example 3: Animal experiments with CV2-PR8 and its use as a backbone to form new strains
[0145] 3.1. Experimental Animals:
[0146] SPF BALB / c mice, female, 6-7 weeks old, weighing 16-18 g, were purchased from Beijing Huafukang Biotechnology Co., Ltd.
[0147] 3.2 Test steps
[0148] The experimental mice were divided into three groups, 5 in each group. The first group was intranasally inoculated with 25 μL of 1× PBS as a control, and the second group was intranasally inoculated with 25 μL of 10 6 EID 50 / 50 μL of PR8 wild influenza virus (WT-PR8 in Example 1), the third group was infected with 25 μL of 10 6 EID 50 / 50μL of CV2-PR8 influenza virus, monitor its survival (mouse death and weight loss of 25% or more are considered death), and collect blood and separate serum 14 days after immunization to measure HI antibody titer. The survival and HI antibody status of mice at 14 days are shown in the table. There was no obvious weight loss in the PBS control group and the CV1-PB1 group within 14 days, and the mortality rate was 0%, while the mortality rate of mice in the WT-PR8 group with the same dose reached 100%, indicating that CV2-PR8 has achieved the purpose of attenuation and has a certain safety. The HI antibodies after 14 days of immunization were all higher than 1:40, indicating that the antibodies produced after CV2-PR8 nasal drops have a protective effect (Table 2).
[0149] 10 of them 6 EID 50 The preparation method of CV2-PR8 influenza virus at 50 μL is as follows: dilute CV2-PR8 to 106 EID 50 / 50μL.
[0150] 10 6 EID 50 The preparation method of PR8 wild influenza strain / 50 μL refers to CV2-PR8 influenza virus.
[0151] 3.3. HI antibody titer determination method
[0152] Take 20 μL of the separated serum in a 1.5 mL EP tube, add 80 μL of RBD and mix, incubate at 37°C for 16-18 hours, inactivate at 56°C for 30 minutes, add 20% red blood cell mud and mix, then incubate at 37°C for 1 hour, repeatedly invert and mix during this period; centrifuge at 1000×g to aspirate the supernatant, which is the treated serum, and place at 4°C for use. Use an eight-channel pipette to add 25 μL of 1×PBS to each well of the 96-well V-type hemagglutination plate. Then use a single-channel pipette to add 25 μL of treated serum to the first well of the 96-well V-type hemagglutination plate, pipette and mix, then use an eight-channel pipette to aspirate 25 μL from the first well to the second well, pipette and mix, dilute in turn to the 11th well, and discard 25 μL. Add 25 μL of saline or PBS to the 12th well as a negative control. Use an eight-channel pipette to add 25 μL of 4HAU virus solution in sequence, incubate at 37°C (room temperature) for 30 min, add 1% chicken red blood cell suspension, leave at room temperature for 15-20 min, and observe the results.
[0153] Result determination: Tilt the reaction plate at 45°, and the red blood cells that settle at the bottom of the well flow linearly downward along the inclined surface as sedimentation, indicating that the red blood cells have not been or are not completely agglutinated by the virus; if the red blood cells at the bottom of the well flatten the bottom of the well and form a uniform thin layer, and the red blood cells do not flow after tilting, it indicates that the red blood cells are agglutinated by the virus or the blood agglutination plate is placed. The highest dilution that completely inhibits the agglutination of red blood cells is taken as the determination end point, that is, the HI titer.
[0154] Table 2: Animal experiment results
[0155] Strain name Mouse mortality rate Weight loss 14dpi HI antibody titer 1× PBS 0% No significant decrease 0 Wt 100% >25% All deaths in 14 days without testing CV1-PR8 0% No significant decrease All 5 mice >1:40
[0156] Example 4. Virus Construction
[0157] 4.1. Reverse genetics virus rescue
[0158] MDCK:293T were plated in a six-well plate at a ratio of 1:5-10 and incubated in DMEM containing 10% fetal bovine serum and double antibody at 37°C and 5% CO. 2The cells were cultured in an incubator for 16-20 h before transfection experiments. During transfection, the recombinant plasmids pHW2000-CV2-PB2, pHW2000-CV2-PB1, pHW2000-CV2-NP, pHW2000-CV2-PA, pHW2000-CV2-M, pHW2000-CV2-NS, pHW2000-HA (HA of the strains shown in Table 3), pHW2000-NA (NA of the strains shown in Table 3) and the transfection reagent Lipofectamine 2000 (500 ng of each recombinant plasmid and 10 μL of transfection reagent were added to each well of the six-well plate) and mixed evenly, and then allowed to stand for 5 minutes. The two were then mixed, and the mixture was allowed to stand for 20 minutes. The mixture was evenly added to the six-well plate and gently shaken to disperse the mixture evenly, and then placed at 33°C for 6-8 hours before changing the medium, and each well was added with 1 μg / mL Opti-MEM containing TPCK-trypsin (Sigma-Aldrich) was placed at 33°C and 5% CO 2 After culturing in an incubator for 72 hours, two 9-11 day old SPF chicken embryos were inoculated with 500 μL of each chicken embryo. The cells were cultured in a 33°C incubator for 96 hours and then placed at 4°C overnight. The chicken embryo allantoic fluid was then collected and its hemagglutination titer was measured with 1% chicken blood (Beijing Hu Te Biotechnology Co., Ltd.). If there was a hemagglutination titer, the target strain was obtained.
[0159] The preparation of recombinant plasmids pHW2000-CV2-PB2, pHW2000-CV2-PB1, pHW2000-CV2-NP, pHW2000-CV2-PA, pHW2000-CV2-M, pHW2000-CV2-NS, pHW2000-HA (HA of the strains shown in Table 3), and pHW2000-NA (NA of the strains shown in Table 3) is described in Example 1, except that the cDNA is replaced accordingly. The cDNA molecules of HA and NA can be directly synthesized with reference to the genome information of the strains shown in Table 3.
[0160] 4.2. Reassortant viruses obtained through natural infection
[0161] Dilute CV2-PR8 to 10 -3 , respectively mixed with the strains in the table in equal volumes, inoculated with chicken embryos, 200 μL per chicken embryo, placed in a 37°C incubator for 72 hours, and the chicken embryo allantoic fluid was collected. The harvested chicken embryo allantoic fluid was mixed with an equal volume of anti-PR8 serum, neutralized at 37°C for 2 hours, and then inoculated with chicken embryos (100 μL / piece), incubated at 25°C for 96 hours, and then the chicken embryo allantoic fluid was collected, and then neutralized with antiserum and then inoculated with chicken embryos. A total of 4 antiserum cycles were performed, and the hemagglutination titer (1% chicken blood cells) was measured.
[0162] The preparation method of anti-PR8 serum is as follows: after inactivating WT-PR8 with β-propiolactone, mix it with aluminum adjuvant according to the method described in the instructions and emulsify it, immunize rabbits (New Zealand white rabbits and 70 days old) by intramuscular injection, and collect blood and separate serum after multiple immunizations. Specifically, the injection volume of each rabbit is 500μL-1mL, and the inactivated WT-PR8 immunization dose in the first immunization is 100μg / rabbit. Two weeks after the first immunization, the inactivated WT-PR8 is mixed with aluminum adjuvant at an immunization dose of 100μg / rabbit for booster immunization. The booster immunization is performed every two weeks, for a total of 4 booster immunizations. Blood is collected from rabbits during the immunization interval, about 5mL is collected each time, and the supernatant is taken at 2000rpm for 5min to obtain the immune serum of the WT-PR8 immunization group. All blood can be collected if the HI titer is ≥1 280.
[0163] Table 3: Influenza A strain information
[0164]
[0165] In the present invention, the inactivated vaccine skeleton strain A / Puerto Rico / 8 / 34 (H1N1) of existing chicken embryo adaptation is selected to be transformed as the basic virus strain, the technical method of cold adaptation passage with reverse genetics technology is constructed to be applicable to the H1N1 subtype cold adaptation vaccine skeleton strain of chicken embryo breeding, for producing cold adaptation vaccine on the basis of not changing the chicken embryo vaccine production line provides technical support, improves the possibility of changing vaccine conversion actual production. The cold adaptation site found in the present invention can greatly weaken the replication ability of strain at 37 ℃, and can make strain well replicate at low temperature (33 ℃ and 25 ℃), the replication ability under these three temperature conditions meets the requirement of replication ability of cold adaptation attenuated influenza vaccine at different temperatures, shows that the strain containing these sites has the potential to become attenuated live vaccine skeleton.
[0166] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. Biomaterials for constructing recombinant influenza A viruses, Features: The biological material is selected from any one of the following B1) to B7): B1) a protein composition, wherein the protein composition comprises a PB2 mutant protein, a PB1 mutant protein, a PA mutant protein, a NP mutant protein, an M1 mutant protein and an M2 mutant protein, The PB2 mutant protein is selected from A1) or A2): A1), a protein having an amino acid sequence of SEQ ID No. 1; A2), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1); The PB1 mutant protein is selected from A3) or A4): A3), a protein having an amino acid sequence of SEQ ID No. 2; A4), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A3); The PA mutant protein is selected from A5) or A6): A5), a protein having an amino acid sequence of SEQ ID No. 3; A6), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A5); The NP mutant protein is selected from A7) or A8): A7), a protein having an amino acid sequence of SEQ ID No. 4; A8), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A7); The M1 mutant protein is selected from A9) or A10): A9), a protein having an amino acid sequence of SEQ ID No. 7; A10), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A9); The M2 mutant protein is selected from A11) or A12): A11), a protein having an amino acid sequence of SEQ ID No. 8; A12), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A11); B2), a set of DNA molecules encoding the protein composition described in B1), wherein the set of DNA molecules comprises a DNA molecule encoding the PB2 mutant protein, a DNA molecule encoding the PB1 mutant protein, a DNA molecule encoding the PA mutant protein, a DNA molecule encoding the NP mutant protein, and a DNA molecule encoding the M1 mutant protein and the M2 mutant protein, B3), a complete set of vectors, including the following B3a), B3b), B3c), B3d) and B3e), B3a), a recombinant vector containing the DNA molecule encoding the PB2 mutant protein in B2); B3b), a recombinant vector containing the DNA molecule encoding the PB1 mutant protein in B2); B3c), a recombinant vector containing the DNA molecule encoding the PA mutant protein in B2); B3d), a recombinant vector containing the DNA molecule encoding the NP mutant protein in B2); B3e), a recombinant vector containing the DNA molecules encoding the M1 mutant protein and the M2 mutant protein in B2); B4), a microorganism containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3); B5) Animal cell lines containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3); B6) Animal tissues containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3); B7) Animal organs containing the complete set of DNA molecules described in B2) or the complete set of vectors described in B3).
2. The biomaterial according to claim 1, Features: The nucleotide sequence of the DNA molecule encoding the PB2 mutant protein is SEQ ID No. 31; The nucleotide sequence of the DNA molecule encoding the PB1 mutant protein is SEQ ID No. 32; The nucleotide sequence of the DNA molecule encoding the PA mutant protein is SEQ ID No. 33; The nucleotide sequence of the DNA molecule encoding the NP mutant protein is SEQ ID No. 34; The nucleotide sequence of the DNA molecule encoding the M1 mutant protein and the M2 mutant protein is SEQ ID No.
36.
3. Recombinant influenza A virus, Features: The recombinant influenza A virus expresses or contains the protein composition described in claim 1.
4. The recombinant influenza A virus according to claim 3, Features: The genome of the recombinant influenza A virus is a single-stranded negative-stranded segmented RNA, and the single-stranded negative-stranded segmented RNA is transcribed to obtain a set of positive-stranded RNAs complementary to the single-stranded negative-stranded segmented RNA, and the set of positive-stranded RNAs includes PB2-RNA, PB1-RNA, PA-RNA, NP-RNA and M-RNA. The PB2-RNA is an RNA molecule encoding the PB2 mutant protein described in claim 1; The PB1-RNA is an RNA molecule encoding the PB1 mutant protein described in claim 1; The PA-RNA is an RNA molecule encoding the PA mutant protein described in claim 1; The NP-RNA is an RNA molecule encoding the NP mutant protein described in claim 1; The M-RNA is an RNA molecule encoding the M1 mutant protein and the M2 mutant protein described in claim 1.
5. The recombinant influenza A virus according to claim 4, Features: The PB2-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.11; The PB1-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.12; The PA-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.13; The NP-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.14; The M-RNA is an RNA molecule whose nucleotide sequence is SEQ ID No.
16.
6. The recombinant influenza A virus according to any one of claims 3 to 5, Features: The strain number of the recombinant influenza A virus is CV2-A / PuertoRico / 8 / 1934 (PR8) (H1N1), and the deposit number of the General Microbiological Center of China National Microbiological Culture Collection is CGMCC No.45374.
7. Method for constructing recombinant influenza A virus, Features: The method comprises M1) or / and M2), M1), introducing the set of vectors described in claim 1, a recombinant vector containing a gene encoding the NS protein of influenza A virus, a recombinant vector containing a gene encoding the HA protein of pandemic influenza A virus, and a recombinant vector containing a gene encoding the NA protein of the pandemic influenza A virus into cells to obtain a recombinant influenza A virus containing the HA and NA of the pandemic influenza A virus; M2), the recombinant influenza A virus according to any one of claims 3 to 6 is mixed and cultured with the pandemic influenza A virus to obtain the recombinant influenza A virus containing the pandemic influenza A virus HA and NA; the mixed culture is to mix the recombinant influenza A virus and the pandemic influenza A virus in equal volumes, inoculate chicken embryos, inoculate 200 μL per chicken embryo, place them in a 37°C incubator for 72 h, and collect the chicken embryo allantoic fluid; the harvested chicken embryo allantoic fluid is mixed with equal volumes of anti-PR8 serum, neutralized at 37°C for 2 h, and then inoculated into chicken embryos, 100 μL per embryo, cultured at 25°C for 96 h, then collect the chicken embryo allantoic fluid, then continue to neutralize with antiserum and then inoculate chicken embryos, perform a total of 4 antiserum cycles, measure the hemagglutination titer, and obtain the recombinant influenza A virus containing the pandemic influenza A virus HA and NA.
8. Use of the biological material according to claim 1 or 2 or the recombinant influenza virus according to any one of claims 3 to 6 in the preparation of a drug for preventing and / or treating influenza virus.
9. Use of the biological material according to claim 1 or 2 or the recombinant influenza virus according to any one of claims 3 to 6 in the preparation of influenza vaccines.
10. Flu vaccine, Features: The influenza vaccine uses the recombinant influenza virus according to any one of claims 3 to 6 as a backbone strain or as an active ingredient.
